NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Ownership - Who owns Taysha Gene Therapies?

Insider buying vs selling

Have Taysha Gene Therapies Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kamran AlamCHIEF FINANCIAL OFFICER2025-03-1129,843$1.69
$50.43kSell
Paul B. Manning10% Owner2024-06-271,333,333$2.25
$3.00MBuy

1 of 1

TSHA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TSHA insiders and whales buy or sell their stock.

TSHA Shareholders

What type of owners hold Taysha Gene Therapies Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Avoro Capital Advisors LLC9.76%19,999,999$36.40MInstitution
Morgan Stanley8.60%17,640,366$32.11MInstitution
Fmr LLC7.98%16,365,664$29.79MInstitution
Blackrock Inc6.60%13,531,467$24.63MInstitution
Ra Capital Management LP5.30%10,872,503$19.79MInstitution
Octagon Capital Advisors LP5.10%10,450,000$19.02MInstitution
Ra Session Ii4.40%9,012,837$16.40MInsider
Vanguard Group Inc4.34%8,906,764$16.21MInstitution
Rtw Investments LP4.23%8,672,630$15.78MInstitution
Audentes Therapeutics Inc3.54%7,266,342$13.22MInsider

1 of 3

TSHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TSHA81.51%15.27%Net BuyingNet Selling
ZVRA62.63%22.89%Net SellingNet Selling
ALT39.02%60.98%Net SellingNet Selling
ABSI58.01%38.90%Net SellingNet Selling
ORKA16.86%83.14%Net BuyingNet Buying

Taysha Gene Therapies Stock Ownership FAQ

Who owns Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ: TSHA) is owned by 81.51% institutional shareholders, 15.27% Taysha Gene Therapies insiders, and 3.22% retail investors. Ra Session Ii is the largest individual Taysha Gene Therapies shareholder, owning 9.01M shares representing 4.40% of the company. Ra Session Ii's Taysha Gene Therapies shares are currently valued at $17.48M.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.